Kenvue (KVUE) to Release Earnings on Tuesday

Kenvue (NYSE:KVUE) will release its earnings data before the market opens on Tuesday, May 7th. Analysts expect Kenvue to post earnings of $0.26 per share for the quarter. Kenvue has set its FY guidance at $1.10-1.20 EPS and its FY 2024 guidance at 1.100-1.200 EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. The company’s quarterly revenue was down 2.7% on a year-over-year basis. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Trading Up 0.4 %

NYSE:KVUE opened at $19.20 on Monday. The stock’s fifty day moving average price is $19.82 and its two-hundred day moving average price is $20.12. Kenvue has a 52-week low of $17.82 and a 52-week high of $27.80. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 4.17%. The ex-dividend date is Tuesday, May 7th.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Sanford C. Bernstein assumed coverage on Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. William Blair assumed coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. cut their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. The Goldman Sachs Group started coverage on Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target on the stock. Finally, Royal Bank of Canada dropped their price objective on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.